IPHARMA is a well-established CRO that manages clinical trials in Russia and EAEU. Clinical branch of ChemRar group, and partner of Skolkovo Innovative center.

About us

IPHARMA contract research organization was established as the part of ChemRar High-Tech Center in order to realize the full cycle clinical development of innovative drugs. The company was headed by a team of specialists with an extensive experience in conducting international and local clinical trials.

IPHARMA became a sub-contractor for 10 state contracts in the transfer of international drugs, organization and conduct of clinical trials of innovative drugs.

 

IPHARMA obtained 11 Clinical trial authorizations issued by the Ministry of Health for the conduct of the clinical trials on diabetes mellitus, schizophrenia, hepatitis C, melanoma, lung cancer, ovarian cancer and the prevention of thromboembolic complications in orthopedics.  

 

Based on the newsletter issued by Association of Clinical Trial Organizations (ACTO), IPHARMA keeps the leadership in the number of clinical trials of Russian innovative drugs.

IPHARMA got the status of a common use center of "Skolkovo".

 

IPHARMA obtained 6 Clinical trial authorizations issued by the Ministry of Health for conduct of the clinical trials on HIV, hepatitis C, liver transplantation, prostate cancer, non-Hodgkin's lymphoma, kidney cancer, and bronchial asthma.  

IPHARMA implemented the training program for young clinical trial specialists.

 

Presentations at the conferences "Current issues of pre-clinical and clinical trials of drugs and medical devices" (Saint Petersburg) and "Clinical trials in Russia" (Moscow, Adam Smith Institute).

 

Based on newsletter issued by Association of Clinical Trial Organizations (ACTO), IPHARMA keeps the leadership in the number of clinical trials of Russian innovative drugs.

IPHARMA obtained 13 Clinical trial authorizations issued by the Ministry of Health for conduct of the clinical trials on influenza, rheumatoid arthritis, hepatitis B, hepatitis C, Meniere's disease, ovarian cancer and bronchial asthma.

Opening of a new IPHARMA office at "Skolkovo" Technopark.

Presentations at international conferences: 75th Scientific Sessions ADA, Boston, MA and 51st Annual Meeting DIA, Washington, DC and "Clinical trials in Russia", Adam Smith Institute, Moscow.

 

Based on newsletter issued by Association of Clinical Trial Organizations (ACTO), IPHARMA keeps the leadership in the number of clinical trials of Russian innovative drugs.

IPHARMA obtained 22 Clinical trial authorizations issued by the Ministry of Health for conduct of the clinical trials on diabetes mellitus, cough, hepatitis C, breast cancer, lung cancer, Meniere's disease, metabolic syndrome and acute respiratory viral infection.

Launch of the Pharmacovigilance system for investigational drugs. Seminars in the frame of educational program Pharma’s cool of Skolkovo Open University.

 

Scientific co-operation agreement with First Moscow State Medical University n.a. I.M. Sechenov. Presentations at international conferences: 28th Annual DIA EuroMeeting, Hamburg, Germany, and 52nd Annual Meeting DIA, Philadelphia, PA and "Clinical trials in Russia", Adam Smith Institute, Moscow..

 

Participation in international co-operation programs (Czech Republic, Cuba). Innovative drugs Gozogliptin and Normacore investigated by IPHARMA obtained marketing authorizations.  

Based on newsletter issued by Association of Clinical Trial Organizations (ACTO), IPHARMA keeps the leadership in the number of clinical trials of Russian innovative drugs.

© 2020 IPHARMA

  • Facebook Social Icon
  • LinkedIn Social Icon
  • YouTube Social  Icon
  • Instagram Social Icon